EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted Nanodelivery of WGX50 and Curcumin via Gold Nanoparticles for Alzheimer's Therapy

Madeeha Shahzad Lodhi, Muhammad Maisam, Muhammad Tahir Khan iD, Amina Bibi, Dongqing Wei, Kejie Mou

Journal of Cellular and Molecular Medicine · 2026-02 · 30 (3)

DOI: 10.1111/jcmm.71045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 06.02.2026. Verfasst von Madeeha Shahzad Lodhi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan. Hauptthemen laut MEDLINE: Curcumin, Alzheimer Disease, Gold, Metal Nanoparticles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a progressive neurodegenerative disorder, posing a global health challenge. It affects millions of people, causing cognitive decline and a heavy burden on healthcare systems. Neuroinflammation is a key pathological feature of AD, often associated with the dysregulation of microRNAs such as hsa‐miR‐146a‐5p. WGX50 (N‐[2‐(3,4‐Dimethoxy‐phenyl)‐ethyl]‐3‐phenyl‐acrylamide), a small molecule derived from Zanthoxylum bungeanum Maxim, has antioxidant and anti‐inflammatory activities. While WGX50 demonstrates potent inhibition of neuroinflammation, its poor blood–brain barrier permeability may be improved using targeted delivery strategies. The current study aimed to design a novel nanoconjugate of WGX50 and curcumin with gold nanoparticles (AuNPs) to observe its therapeutic effects in a rat model. All nanoconjugates were synthesised as targeted (Cys‐capped AuNPs with WGX50‐insulin and curcumin‐insulin) and non‐targeted (without insulin). Immunohistochemical analysis revealed that both non‐targeted (WGX50‐NT) and targeted (WGX50‐T) therapies have a significant effect in the rat model, with WGX50‐T showing a more pronounced effect. The histopathology results of WGX50 and WGX50‐T showed an approximate 80%–90% reduction in Aβ plaque deposition. The treatment with both curcumins targeted (C‐T) and non‐targeted (C‐NT) formulations led to a significant reduction in Aβ levels in AD rats. Fluorescence microscopy confirmed that targeted delivery was more effective, potentially leading to better therapeutic outcomes. The expression levels of hsa‐miR‐146a‐5p showed differential expression levels with targeted treatments correlating with lower expression levels, suggesting a role in modulating neuroinflammation and immune responses. Overall, these findings highlight the potential of targeted drug delivery systems in enhancing the efficacy of AD treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CurcuminAlzheimer DiseaseGoldMetal NanoparticlesAnimalsRatsMicroRNAsHumansMaleDisease Models, AnimalDrug Delivery SystemsAmyloid beta-Peptides

Stichwörter der Autor:innen

Alzheimer's diseaseWGX50curcumingold nanoparticlesinsulinmiRNA‐146a‐5ptargeted drug delivery

Substanzen

CurcuminGoldMicroRNAsAmyloid beta-Peptides

Autor:innen und Institutionen

  • Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
  • Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan.
  • International Center for Interdisciplinary Research in Sciences (ICIRS), The University of Lahore, Lahore, Pakistan.
  • State Key Laboratory of Respiratory Disease, Guangzhou Key Laboratory of Tuberculosis Research, Department of Clinical Laboratory, Guangzhou Chest Hospital, Institute of Tuberculosis, Guangzhou Medical University, Guang…
  • State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic & Developmental Sciences and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, P.R. Ch…
  • Zhongjing Research and Industrialization Institute of Chinese Medicine, Nanyang, Henan, PR China.

ORCID-Profile: Muhammad Tahir Khan

Zitieren

APA

Lodhi, M. S., Maisam, M., Khan, M. T., Bibi, A., Wei, D., & Mou, K. (2026). Targeted Nanodelivery of WGX50 and Curcumin via Gold Nanoparticles for Alzheimer's Therapy. Journal of Cellular and Molecular Medicine, 30(3). https://doi.org/10.1111/jcmm.71045

Vancouver

Lodhi MS, Maisam M, Khan MT, Bibi A, Wei D, Mou K. Targeted Nanodelivery of WGX50 and Curcumin via Gold Nanoparticles for Alzheimer's Therapy. Journal of Cellular and Molecular Medicine. 2026;30(3). doi:10.1111/jcmm.71045

BibTeX
@article{Lodhi2026,
  author = {Lodhi, Madeeha Shahzad and Maisam, Muhammad and Khan, Muhammad Tahir and Bibi, Amina and Wei, Dongqing and Mou, Kejie},
  title = {Targeted Nanodelivery of WGX50 and Curcumin via Gold Nanoparticles for Alzheimer's Therapy},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  volume = {30},
  number = {3},
  doi = {10.1111/jcmm.71045}
}
Kostenlos starten →